Tandem Diabetes Care Inc. (TNDM) is a leading medical device company, primarily known for its innovative development and commercialization of products for people with insulin-dependent diabetes. The company is headquartered in San Diego, California, and it has been at the forefront of pioneering advanced diabetes management technology products since its inception in 2006.
Tandem’s core mission is to improve the lives of people with Diabetes through strategic and continuously evolving advancements. The firm emphasizes that it is committed to delivering results that serve this commitment, and offers numerous smart insulin pumps, featuring touch-screen and user-friendly interfaces, aiding patients in effectively managing their Diabetes.
Tandem's flagship product is the t:slim X2 insulin pump, the first insulin pump with a color touchscreen that is user-friendly and easy to read. It's small, discrete, and can deliver insulin more accurately than other insulin pumps. The X2 pump is considered to be one of the most technically advanced insulin pumps available in the market.
Another significant contribution to the field by Tandem Diabetes Care is the development of integrated continuous glucose monitoring systems. The company was the first to develop and release the basal-IQ predictive low-glucose suspend technology, as well as being the first to create a touch screen pump with continuous glucose monitoring integration.
A promising development from Tandem is their Control-IQ Technology, made possible through the strategic collaboration with TypeZero Technologies and DexCom Inc. This technology is designed to aid in adjusting insulin levels through the use of an algorithm that constantly monitors the blood sugar level of a user, delivering insulin as required.
In the past few years, Tandem has enjoyed explosive growth not only domestically, but also on a global scale, driven primarily by its innovative and user-centric product range. The company is being recognized for transforming the management of Diabetes and is highly regarded by users of its products.
Tandem Diabetes Care Inc., belongs to the cutting-edge of diabetes technology, pushing boundaries to make the lives of those with diabetes more manageable. Its focus on user-friendly innovations, partnerships with top companies in the field, and its unwavering commitment to improving the daily lives of people with diabetes collectively make Tandem a significant player within this increasingly important sphere of health technology.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Tandem Diabetes Care Inc (TNDM) recently saw its shares rise by 3.3% to $15.72. According to GuruFocus's GF Value™, the stock is significantly undervalued at 34.8% below its estimated fair value of $24.10, earning it a "Possible Value Trap" label due to its unprofitability and negative cash flow. The company has an above-average GF Score™ of 68/100, bolstered by strong momentum, but faces challenges in financial strength and profitability, with no insider buying activity reported in the past year.
Truist has lowered its price target for Tandem Diabetes Care (TNDM) to $28 from $31, while maintaining a Buy rating on the stock. Tandem Diabetes Care currently holds an average rating of "overweight" with a mean price target of $29. The full MT Newswires article requires a premium subscription to access.
This article analyzes Tandem Diabetes Care Inc. (NASDAQ: TNDM) using algorithmic entry frameworks, highlighting divergent sentiment across different time horizons. It provides three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry points, targets, and stop losses. The analysis also includes multi-timeframe signal strengths and support/resistance levels.
William Blair initiated coverage on Tandem Diabetes Care (TNDM) with an 'Outperform' rating. The stock is considered 7.1% undervalued according to GF Value™, despite the company currently being unprofitable. Tandem Diabetes Care's GF Score™ is 71/100, reflecting strong growth and momentum but weaknesses in financial strength and profitability, warranting careful consideration from investors.